Delivering safe, compliant AI solutions in healthcare normally means months of governance, validation, identity, and audit controls assembled from scratch — the reason most AI stalls before production. Nodalium VIA has that foundation built in and independently accredited, so solutions deploy in weeks and arrive defensible.
ACCREDITED · IN PRODUCTION · ALREADY DELIVERING
Healthcare AI has moved from pilots toward core clinical and operational workflows — and hit a wall. Every consequential deployment now demands governance, risk-tiering, human-in-the-loop, enforced access control, monitoring, and an audit trail you can defend. Regulators, accreditors, and two dozen states have made that non-optional, and underwriters have begun asking whether an organization polices its AI at all.
The exposure runs both ways: using AI carries risk, and failing to use AI that has become standard of care carries it too. The result is enormous, funded demand — gated by a deployment problem no one has productized. That gap is the market.
Nodalium VIA is model-driven: a new solution — a semi-autonomous agent, an AI assistant, a Core-Agent-managed patient encounter through care plan and follow-up with human-in-the-loop — is a configured model on an accredited foundation, not a governance project rebuilt from scratch each time. Four integrated layers:
Production Direct + FHIR + TEFCA, normalized to a common MIME format so orchestration is protocol-agnostic.
Enterprise Flowable on a perpetual, unlimited license. CMMN adaptive case management for agentic workflows.
Operational Contracts, sentries, and guardrails — with policy-based access control for internal and external agent orchestration. Machine-enforced at runtime.
The coordinating intelligence — opens cases, delegates to specialized agents, and validates every action against the Operational Contracts before it executes.
Speed doesn't come from cutting corners. It comes from the corners already being turned — accredited. A compliant solution deploys in weeks because it inherits, rather than rebuilds, the whole control surface:
Two production instances; one processes 20M+ transactions a year, proving the platform at scale on live traffic.
The tier DirectTrust reserves for AI implemented and operational, built on NIST AI RMF. Verifiable now via Credly.
Unlimited orchestration, zero incremental licensing cost at any scale — an arrangement Flowable has called unique.
Every inbound message — Direct, FHIR, TEFCA — normalized before it enters the workflow engine. Protocol-agnostic.
The operational system of record that earned the AI accreditation — governance you can run and audit, not just claim.
Dedicated tenant namespaces from a parameterized Helm chart. GitOps-ready with ArgoCD + Helm.






Being through the wall while others aren't means demand arrives inbound. What's already forming:
An existing customer that is also a distribution channel into a large rural footprint — the on-ramp for normalized Direct→FHIR→TEFCA messaging.
Multi-million QHIN discussions, and Rural Health Transformation participants who must actually deploy the solutions they proposed against a $50B program.
The accredited Governance Console sells fast — compliance buyer, no PHI, short cycle — then the same Operational Contracts govern live VIA workflows.
The question isn't whether the foundation works — it does, in production. It's how much becomes addressable once safe deployment stops being a months-long project and becomes a configuration on an accredited platform.
~$500K in AI-platform ARR — annually prepaid, auto-renewing, and already renewed across multiple cycles. Every dollar of it was won inbound: customers came to us because the production infrastructure and accreditations are real. We have not yet gone to market. This round funds the go-to-market.
The company runs near break-even on a modest burn, with a recurring base partially offsetting cost — so the raise funds growth, not survival. A typical company at this stage raises to find demand; Nodalium raises to serve demand it has already proven exists.
AI capability is commoditizing; regulated-market trust is not. Nodalium's team helped write the standards it builds on — leadership roles in HL7 and DirectTrust — and has operated accredited healthcare exchange infrastructure for years. The rails, the accreditations, and the standards position took time and operating history to earn; they can't be bought with a bigger model or a bigger round.
Active leadership in HL7 and DirectTrust — shaping the interoperability and AI-accreditation standards the market is adopting.
Years running accredited HISP, security, and AI-governed infrastructure in production — the proving ground for the platform.
[Founder / key-executive bios and the incoming senior commercial hire to be added.]
Nodalium is raising a $4M round to switch on the go-to-market motion behind revenue that already arrives inbound. The capital funds commercial launch and platform delivery to a defined year-end commercial milestone — not construction, which is already done.
Illustrative allocation. The round is a single-cap rolling close — committed capital is put to work as it arrives, sized to reach the year-end commercial milestone.
Verify your identity to access the round terms. One quick step to your email — no password to create. The verification runs on our own accredited identity service.